HIV-1 encephalopathy among perinatally infected children: Neuropathogenesis and response to highly active antiretroviral therapy

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 12, Issue 3, 2006, Pages 216-222

  Mitchell, Charles D ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Central nervous system (CNS) neuropathogenesis; HAART; HIV encephalopathy

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EXCITATORY AMINO ACID; GLYCOPROTEIN GP 120; INTERLEUKIN 1BETA; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MATRIX METALLOPROTEINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

APOPTOSIS; ASTROCYTOSIS; BRAIN DISEASE; CEREBROSPINAL FLUID; CHILD; DENDRITIC CELL; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; MEMBRANE DAMAGE; MICROCEPHALY; MOTOR NEURON DISEASE; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPATHOLOGY; PERINATAL INFECTION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PYRAMIDAL SIGN; REVIEW; SYNAPTIC MEMBRANE; UNITED STATES; VIRUS ENCEPHALITIS;

ADULT; AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; CHILD; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; DISEASE TRANSMISSION, VERTICAL; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MENTAL RETARDATION; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33750433582     PISSN: 10804013     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/mrdd.20111     Document Type: Review

References (51)

1. Albright AL. 2003. Neurosurgical treatment of spasticity and other pediatric movement disorders. J Child Neurol 18:S67-S78.
2. Belman A, Taylor F, Nachman S, et al. 1994. HIV-1 associated CNS disease syndromes in infants and children. Neurology 44:168, 169.
3. Blanche S, Newell M, Mayaux M, et al. 1997. Morbidity and mortality in European children vertically infected by HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 14:442-450.
4. Brew BJ, Pemberton L, Cunningham P, et al. 1997. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 175:963-966.
5. Brouwers P, Belman A, Epstein L. 1991. Central nervous system involvement: Manisfestations and evaluation. In: Pizzo P, Wilfert C, editors. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents. Baltimore: Williams & Wilkins. pp 318-335.
6. Brouwers P, Moss H, Wolters P, et al. 1990. Efect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J Pediatr 117:980-985.
7. Brouwers P, Wolters P, Civitello L. 1998. Central nervous system manifestations and assessment. In: Pizzo P, Wilfert CM, editors. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents, 3rd ed. Baltimore: Williams & Wilkins. pp 293-308.
8. Budka H. 1991. Consensus report HIV-associated disease of the nervous system: Review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol 1:143-152.
9. Chiriboga CA, Fleishman S, Champion S, et al. 2005. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active antiretroviral therapy (HAART). J Pediatr 146:402-407.
10. Civitello L. 2005. Neurologic problems. In: Zeichner S, Read J, editors. Textbook of Pediatric HIV Care. New York: Cambridge University Press, pp 431-444.
11. Civitello L, Brouwers P, Pizzo P. 1993. Neurologic and neuropsychologic manifestations in 120 children with symptomatic HIV infection. Ann Neurol 34:481.
12. Cunningham P, Smith D, Satchell C, et al. 2000. Evidence for independent development of reverse transcriptase inhibitor resistance patterns in the cerebrospinal fluid. AIDS 14:1949-1954.
13. Cysique LA, Maruff P, Brew BJ. 2004. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: A combined study of two cohorts. J Neurovirol 10:350-357.
14. de Martino M, Tovo PA, Balducci M, et al. 2000. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 284:190-197.
15. Eggers C, Hertogs K, Sturenburg H, et al. 2003. Delayed CNS virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor CNS drug penetration. AIDS 17:1897-1906.
16. Ellis RJ, Moore DJ, Childers ME, et al. 2002. Progression to neuropsychologic impairment in HIV infection predicted by elevated CSF levels of HIV RNA. Arch Neurol 59:342-347.
17. England J, Baker C, Raskino C, et al. 1996. Clinical and laboratory characteristics of a large cohort of symptomatic HIV-infected infants and children. Pediatr Infect Dis 15:1025-1036.
18. Epstein L, Sharer L. 1998. Neurology of HIV infection in children. In: Rosenblum M, Levy R, Bresden D, editors. AIDS and the Nervous System. New York: Raven Press, pp 79-101.
19. Floeter M, Civitello L, Everett C. 1997. Peripheral neuropathy in children with HIV infection. Neurology 49:207-212.
20. Gallo P, Sivieri S, Rinaldi L, et al. 1994. Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the CNS. J Neurol Sci 126:49-53.
21. Gendelman H, Diesing S, Gelbard H, et al. 2004. The neuropathogenesis of HIV infection. In: Wormser GP, editor. AIDS and Other Manifestations of HIV Infection, 4th ed. Amsterdam: Elsevier. Ch 5, pp 95-115.
22. Geraci AP, Simpson DM. 2001. Neurological manifestations of HIV infection in the HAART era. Compr Ther 27:232-241.
23. Gortmaker S, Hughes M, Cervia J, et al. 2001. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 345:1522-1528.
24. Jeremy RJ, Kim S, Nozyce M, et al. 2005. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics 115:380-387.
25. Kalams S, Walker B. 1995. Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Curr Top Microbiol Immunol 202:79-88.
26. Kaul M, Lipton SA. 1999. Chemokines and activated macrophages in gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 96:8212-8216.
27. Kaul M, Lipton S. 2004. Signaling pathways to neuronal damage and apoptosis in human immunodeficiency virus type 1-associated dementia: Chemokine receptors, excitotoxicity, and beyond. J Neurovirol 10 (Suppl 1):97-101.
28. Kaul M, Zheng J, Okamoto S, et al. 2005. HIV-1 infection and AIDS: Consequences for the CNS. Cell Death Differ 12:878-892.
29. Koppel BS, Akfirat GL. 2004. Neurologic complications of HIV and AIDS. In: Wormser GP, editor. AIDS and Other Manifestations of HIV Infection, 4th ed. Amsterdam: Elsevier. Ch 18, pp 479-535.
30. Leonard W. 2003. Type I cytokines and interferons and their receptors. In: Paul WE, editor. Fundamental Immunology. Philadelphia: Lippincott. pp 701-741.
31. Lu D, Pavlakis S, Frank Y, et al. 1996. Proton MR spectroscopy of the basal ganglia in healthy children and children with AIDS. Radiology 199:423-428.
32. Maldonado Y. 2006. Acquired immunodeficiency syndrome in the infant. In: Remington J, Klein J, Wilson C, Baker C, editors. Infectious Diseases of the Fetus and Newborn Infant. Philadelphia: Elsevier/Saunders. pp 667-692.
33. McCoig C, Castrejon MM, Castano E, et al. 2002. Effects of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatr 141:36-44.
34. Mellgren A, Antinori A, Cinque P, et al. 2005. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 10:701-707.
35. Mintz M. 1999. Clinical features and treatment interventions for HIV-associated neurologic disease in children. Semin Neurol 19:165-176.
36. Mofenson L, Wilfert C. 1998. Pathogenesis and interruption of vertical transmission. In: Pizzo P, Wilfert CM, editors. Pediatric Aids. Baltimore: Williams & Wilkins. pp 487-513.
37. Nath A. 1999. Pathobiology of HIV dementia. Semin Neurol 19:113-127.
38. Neuenburg JK, Brodt HR, Herndier BG, et al. 2002. HIV-related neuropathy, 1985-1999: Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31:171-177.
39. Nottett HS, Shawan S. 1998. HIV-1 entry into brain. Mechanisms for the infiltration of HIV-1 infected macrophages across the blood-brain barrier. In: Gendelman HE, Lipton SA, Epstein L, Swindells S, editors. The Neurology of AIDS. New York: Chapman & Hall, pp 49-60.
40. Persidsky Y, Zheng J, Miller D, et al. 2001. Mononuclear phagocytes mediate blood brain barrier compromise and neuronal injury during HIV-1 associated dementia. J Leukoc Biol 68:413-422.
41. Pizzo PA, Eddy J, Faloon J, et al. 1988. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Eng J Med 319:889-896.
42. Prospero-Garcia O, Gold L, Fox H, et al. 1996. Microglia-passaged simian immunodeficiency virus induces neurophysiological abnormalities in monkeys. Proc Natl Acad Sci USA 93:14158-14163.
43. Sacktor N, Lyles RH, Skolasky R, et al. 2001. HIV-associated neurologic disease incidence changes: Multicenter AIDS cohort study, 1990-1998. Neurology 56:257-260.
44. Shanbhag MC, Rutstein RM, Zaoutis T, et al. 2005. Neurocognitive functioning in pediatric human immunodeficiency virus infection: Effects of combined therapy. Arch Pediatr Adolesc Med 159:651-656.
45. Smith R, Malee K, Charuat M, et al. 2000. Timing of perinatal HIV-1 infection and rate of neuredevelopment. Pediatr Infect Dis J 19:862-971.
46. Smit TK, Brew BJ, Tourtellotte W, et al. 2004. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatments. J Virol 78:10133-10148.
47. Strain MC, Letendre S, Pillai SK, et al. 2005. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol 79:1772-1788.
48. Tamula MA, Wolters PL, Walsek C, et al. 2003. Cognitive decline with immunologic and virlogic stability in four children with human immunodeficiency virus disease. Pediatrics 112(3, Part 1):679-684.
49. Tardieu M, LeChenadec J, Persoz A, et al. 2000. HIV-1 related encephalopathy in infants compared with children and adults. Neurology 54:1089-1095.
50. Willen E. Neurocognitive outcomes in pediatric HIV. Ment Retard Dev Disabil Res Rev (in press).
51. Zinc MC, Uhrlaub J, DeWitt J, et al. 2005. Neuroprotective and anti-human immunodeficiency virus activity of minocyclme. JAMA 293:2003-2011.